Yes, I figured it was our original manufacturer. I thought the language changed, but just compared to the 10-K and it matches identical....so no changes since Samsung was announced.

Possibly they are going with their current CMO initially to meet the demands and avoid the $8.3M penalty along with the added benefit they are US based and history producing leronlimab. Likely nothing significant, just looking forward to approval and would hate to see demand outpace supply (wouldn't be the worst problem to have though).